secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0001104659-21-151970
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharma gets FDA IND clearance for CRV431 in liver cancer (HCC), enabling direct Phase 2 start
--------------------------------------------------------------------------------

- FDA accepted IND for CRV431 for hepatocellular carcinoma; allows Phase 2 trial to begin without Phase 1.
- CRV431 is a liver-targeting cyclophilin inhibitor; also being studied for NASH with Phase 2b ASCEND-NASH expected in 2022.
- Positive Phase 2a AMBITION NASH data previously reported; CRV431 well-tolerated with all primary endpoints met.
- Company highlights CRV431's oral dosing and potential anti-tumor mechanisms including immune modulation.
- Expansion into HCC complements existing NASH pipeline with a single once-daily oral agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465921151970/0001104659-21-151970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465921151970/tm2135984d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-151970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer